Novo Nordisk (NVO) Revenue & Revenue Breakdown
Novo Nordisk Revenue Highlights
Latest Revenue (Y)
$232.26B
Latest Revenue (Q)
$65.35B
Main Geography (Y)
North America
Novo Nordisk Revenue by Period
Novo Nordisk Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $232.26B | 31.26% |
| 2022-12-31 | $176.95B | 25.68% |
| 2021-12-31 | $140.80B | 10.91% |
| 2020-12-31 | $126.95B | 4.04% |
| 2019-12-31 | $122.02B | 9.11% |
| 2018-12-31 | $111.83B | 0.12% |
| 2017-12-31 | $111.70B | -0.08% |
| 2016-12-31 | $111.78B | 3.57% |
| 2015-12-31 | $107.93B | 21.53% |
| 2014-12-31 | $88.81B | 6.26% |
| 2013-12-31 | $83.57B | 7.11% |
| 2012-12-31 | $78.03B | 17.60% |
| 2011-12-31 | $66.35B | 9.16% |
| 2010-12-31 | $60.78B | 18.99% |
| 2009-12-31 | $51.08B | 11.85% |
| 2008-12-31 | $45.67B | 9.02% |
| 2007-12-31 | $41.89B | 8.09% |
| 2006-12-31 | $38.75B | 14.94% |
| 2005-12-31 | $33.71B | 15.33% |
| 2004-12-31 | $29.23B | 9.85% |
| 2003-12-31 | $26.61B | 5.80% |
| 2002-12-31 | $25.15B | 6.06% |
| 2001-12-31 | $23.72B | 13.94% |
| 2000-12-31 | $20.82B | -0.62% |
| 1999-12-31 | $20.94B | 16.94% |
| 1998-12-31 | $17.91B | 5.45% |
| 1997-12-31 | $16.98B | 13.96% |
| 1996-12-31 | $14.90B | 8.68% |
| 1995-12-31 | $13.71B | 1.44% |
| 1994-12-31 | $13.52B | 2.83% |
| 1993-12-31 | $13.15B | - |
Novo Nordisk generated $232.26B in revenue during NA 2023, up 31.26% compared to the previous quarter, and up 207.69% compared to the same period a year ago.
Novo Nordisk Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $65.35B | -0.78% |
| 2023-12-31 | $65.86B | 12.14% |
| 2023-09-30 | $58.73B | 8.16% |
| 2023-06-30 | $54.30B | 1.75% |
| 2023-03-31 | $53.37B | 10.97% |
| 2022-12-31 | $48.09B | 5.54% |
| 2022-09-30 | $45.57B | 10.42% |
| 2022-06-30 | $41.27B | -1.82% |
| 2022-03-31 | $42.03B | 9.65% |
| 2021-12-31 | $38.33B | 7.61% |
| 2021-09-30 | $35.62B | 7.81% |
| 2021-06-30 | $33.04B | -2.26% |
| 2021-03-31 | $33.80B | 5.18% |
| 2020-12-31 | $32.14B | 3.92% |
| 2020-09-30 | $30.93B | 3.07% |
| 2020-06-30 | $30.01B | -11.42% |
| 2020-03-31 | $33.88B | 4.50% |
| 2019-12-31 | $32.42B | 7.07% |
| 2019-09-30 | $30.28B | 0.80% |
| 2019-06-30 | $30.04B | 2.54% |
| 2019-03-31 | $29.29B | -1.48% |
| 2018-12-31 | $29.73B | 7.10% |
| 2018-09-30 | $27.76B | 1.30% |
| 2018-06-30 | $27.41B | 1.77% |
| 2018-03-31 | $26.93B | -3.79% |
| 2017-12-31 | $27.99B | 5.18% |
| 2017-09-30 | $26.61B | -7.07% |
| 2017-06-30 | $28.64B | 0.65% |
| 2017-03-31 | $28.45B | -3.79% |
| 2016-12-31 | $29.57B | 7.39% |
| 2016-09-30 | $27.54B | 0.28% |
| 2016-06-30 | $27.46B | 0.91% |
| 2016-03-31 | $27.21B | -5.76% |
| 2015-12-31 | $28.88B | 7.78% |
| 2015-09-30 | $26.79B | -0.99% |
| 2015-06-30 | $27.06B | 7.38% |
| 2015-03-31 | $25.20B | 2.50% |
| 2014-12-31 | $24.59B | 10.50% |
| 2014-09-30 | $22.25B | 2.87% |
| 2014-06-30 | $21.63B | 6.32% |
| 2014-03-31 | $20.34B | -6.24% |
| 2013-12-31 | $21.70B | 5.79% |
| 2013-09-30 | $20.51B | -4.06% |
| 2013-06-30 | $21.38B | 6.99% |
| 2013-03-31 | $19.98B | -4.67% |
| 2012-12-31 | $20.96B | 5.63% |
| 2012-09-30 | $19.84B | 1.94% |
| 2012-06-30 | $19.47B | 9.67% |
| 2012-03-31 | $17.75B | -2.04% |
| 2011-12-31 | $18.12B | 9.61% |
| 2011-09-30 | $16.53B | 3.32% |
| 2011-06-30 | $16.00B | 1.96% |
| 2011-03-31 | $15.69B | -2.67% |
| 2010-12-31 | $16.12B | 3.47% |
| 2010-09-30 | $15.58B | 1.23% |
| 2010-06-30 | $15.39B | 12.58% |
| 2010-03-31 | $13.67B | 4.69% |
| 2009-12-31 | $13.06B | 4.35% |
| 2009-09-30 | $12.52B | -3.72% |
| 2009-06-30 | $13.00B | 4.02% |
| 2009-03-31 | $12.50B | -1.77% |
| 2008-12-31 | $12.72B | 13.23% |
| 2008-09-30 | $11.24B | 1.11% |
| 2008-06-30 | $11.11B | 4.80% |
| 2008-03-31 | $10.60B | - |
Novo Nordisk generated $65.35B in revenue during Q1 2024, up -0.78% compared to the previous quarter, and up 135.88% compared to the same period a year ago.
Novo Nordisk Revenue Breakdown
Novo Nordisk Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Rest of World | $28.08B | $25.40B | $19.81B |
| North America | $136.63B | $91.11B | $67.26B |
| EMEA | $50.87B | $44.24B | $37.71B |
Latest
Novo Nordisk's latest annual revenue breakdown by geography, as of Dec 23: North America (63.38%), EMEA (23.60%), and Rest of World (13.02%).
Novo Nordisk Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| NVO | Novo Nordisk | $232.26B | $65.35B |
| REGN | Regeneron Pharmaceuticals | $13.12B | $3.72B |
| VRTX | Vertex Pharmaceuticals | $9.84B | $2.77B |
| MRNA | Moderna | $6.85B | $1.86B |
| BNTX | BioNTech SE | $3.82B | $187.60M |
| BMRN | BioMarin Pharmaceutical | $2.42B | $733.87B |
| ALNY | Alnylam Pharmaceuticals | $1.83B | $420.15M |
| SRPT | Sarepta Therapeutics | $1.24B | $362.93M |
| NVAX | Novavax | $983.71M | $415.48M |
| CRSP | CRISPR Therapeutics | $370.00M | $602.00K |
| DNA | Ginkgo Bioworks | $251.46M | $89.05M |
| TGTX | TG Therapeutics | $233.66M | $83.88M |
| CVAC | CureVac | $52.70M | $12.37M |
| NTLA | Intellia Therapeutics | $36.27M | $9.11M |
| CWBR | CohBar | - | - |
| MDGL | Madrigal Pharmaceuticals | - | $62.17M |
| TERN | Terns Pharmaceuticals | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |